Skip to main content
Equibles
DMAA logo

DMAA · Drugs Made In America Acquisition Corp. · Metrics

Track DMAA — free

Use DMAA with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research DMAA.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$10.90
Rebalance outlook locked
Going-concern doubt — flagged Aug 14, 2026

Substantial doubt about the company's ability to continue as a going concern.

“Additionally, the date for mandatory liquidation and subsequent dissolution raise substantial doubt about the Company’s ability to continue as a going concern. These conditions raise substantial doubt about the Company’s ability to continue as a going concern within one year after the date that the financial statements are issued. Management plans to address this uncertainty through a Business Combination. There is no assurance that the Company’s plans to raise capital or to consummate a Business Combination will be successful within the Combination Period.”
View the 10-Q filed Aug 14, 2026
Market Cap
$264.29M
Shares
24.28M
Volume · Oct 1 925 Avg daily vol (3M) 34.91K

DMAA metrics

44 of 115 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$10.89
Market cap
$264.29M

Price action

20 metrics
Price change (1W)
+0.4%
Price change (30D)
+0.9%
Price change (3M)
+2.3%
Price change (6M)
+3.6%
Price change (YTD)
+5.0%
Price change (1Y)
+6.1%
Trailing year
Price change (5Y)
—
52-week high
$10.89
52-week low
$10.26
Change from 52-week high
+0.0%
Change from 52-week low
+6.1%
Annualized volatility
2.0%
Annualized volatility (3M)
—
Beta
0.0
RSI (14D)
84.9
Price vs SMA 50
+1.3%
Price vs SMA 200
+3.3%
Avg volume (3M)
34,911
Relative volume
0.0
Average dollar volume
$374,709

Company

3 metrics
Sector
Financial Services
Industry
Shell Companies
Shares outstanding
24.28M

Valuation

12 metrics
P / E (TTM)
43.4
Trailing earnings · reciprocal yield 2.3%
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
—
P / book
—
FCF yield
—
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
2.3%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
—

Profitability

9 metrics
Gross margin
—
Operating margin
—
Trailing 12 months
Net margin
—
Gross profit (TTM)
—
Operating profit (TTM)
−$2.63M
Net income (TTM)
$6.09M
Trailing 12 months
Diluted EPS (TTM)
—
FCF margin
—
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
—
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
—
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
—
Operating cash flow per diluted share (TTM)
—
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
—
Stock compensation per diluted share (TTM)
—
Book value per share
$-0.68

Growth

11 metrics
Revenue growth YoY
—
Year over year
Net income growth YoY
-24.5%
Revenue (TTM)
—
Trailing 12 months
EPS growth YoY
—
Shares change YoY
-27.6%
Year over year · fewer shares
Revenue CAGR (3Y)
—
Revenue CAGR (5Y)
—
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
—
Return on assets
4.1%
Debt / equity
—
Current ratio
0.0
EBITDA (TTM)
—
Free cash flow (TTM)
—
Quick ratio
0.0
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
$20,280
Latest balance sheet
Cash & equivalents
$20,280
Total assets
$146.90M
Total debt
—

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$517,145
Capital expenditures (TTM)
—
R&D (TTM)
—
SG&A (TTM)
—
Stock compensation (TTM)
—
R&D / revenue
—
Stock compensation / revenue
—

Ownership (13F)

3 metrics
13F filers
44
13F filer change QoQ
-8
Institutional ownership
97.2%

Short interest

3 metrics
Short interest
0.4%
Latest settlement · 1.3 days to cover
Days to cover
1.3d
Short-squeeze score
38 / 100

Insider activity

2 metrics
Net insider buying (90D)
—
Insider-sentiment score
—

Risk flags

1 metrics
Going concern
Flagged
Key facts CIK 2028614 CUSIP G2847J104